Radiological Recurrence Patterns after Bevacizumab Treatment of Recurrent High-Grade Glioma: A Systematic Review and Meta-Analysis

Se Jin Cho, MD1, Ho Sung Kim, MD, PhD2, Chong Hyun Suh, MD2, Ji Eun Park, MD, PhD2

1Department of Radiology, Seoul National University Bundang Hospital, Seongnam, Korea; 2Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea

Objective: To categorize the radiological patterns of recurrence after bevacizumab treatment and to derive the pooled proportions of patients with recurrent malignant glioma showing the different radiological patterns.

Materials and Methods: A systematic literature search in the Ovid-MEDLINE and EMBASE databases was performed to identify studies reporting radiological recurrence patterns in patients with recurrent malignant glioma after bevacizumab treatment failure until April 10, 2019. The pooled proportions according to radiological recurrence patterns (geographically local versus non-local recurrence) and predominant tumor portions (enhancing tumor versus non-enhancing tumor) after bevacizumab treatment were calculated. Subgroup and meta-regression analyses were also performed.

Results: The systematic review and meta-analysis included 17 articles. The pooled proportions were 38.3% (95% confidence interval [CI], 30.6–46.1%) for a geographical radiologic pattern of non-local recurrence and 34.2% (95% CI, 27.3–41.5%) for a non-enhancing tumor-predominant recurrence pattern. In the subgroup analysis, the pooled proportion of non-local recurrence in the patients treated with bevacizumab only was slightly higher than that in patients treated with the combination with cytotoxic chemotherapy (34.9% [95% CI, 22.8–49.4%] versus 22.5% [95% CI, 9.5–44.6%]).

Conclusion: A substantial proportion of high-grade glioma patients show non-local or non-enhancing radiologic patterns of recurrence after bevacizumab treatment, which may provide insight into surrogate endpoints for treatment failure in clinical trials of recurrent high-grade glioma.

Keywords: Bevacizumab; Glioblastoma; Magnetic resonance imaging; Radiology

INTRODUCTION

Among various options, bevacizumab is available for the treatment of recurrent glioblastoma. It is a humanized monoclonal antibody that works as an antiangiogenic drug inhibiting vascular endothelial growth factor (VEGF), thereby targeting the high vascularity of glioblastomas (1, 2). Although bevacizumab treatment presents a high radiological response rate of 20–40% (1-3), there are several challenges to its use for the treatment of recurrent glioblastoma, including its short response duration (1-4), limitations in post-treatment tissue confirmation of response, and changes in the behavior of malignant tumors after treatment failure (5, 6). In particular, bevacizumab does not simply reduce angiogenesis but may also trigger treatment failure via several mechanisms, including angiogenesis other than the sprouting pattern of angiogenesis and tumor escape pathways via non-VEGF or VEGF angiogenesis (7-10). This characteristic has become the molecular background for new clinical approaches including combination therapies to overcome the limitations of bevacizumab.

From the radiological aspect, the alteration of
Recurrence Patterns in Recurrent Glioblastoma

Enhancement or signal intensity patterns on magnetic resonance imaging (MRI) makes it harder to evaluate tumor recurrence after bevacizumab treatment (11-14). Against this background, several studies have tried to classify the radiological recurrence patterns after the failure of bevacizumab treatment for recurrent glioblastoma as these patterns may reflect different biological subgroups requiring specific treatment patterns (4, 11-17). According to these studies, the radiological recurrence patterns after bevacizumab treatment failure differed from those of other conditions in which the treatment did not contain bevacizumab (4, 11-13, 16-28). However, there is no established radiological recurrence pattern to define bevacizumab treatment failure in patients with recurrent glioblastoma; thus, there is no conclusive evidence that the specific patterns of progression after bevacizumab treatment can be associated with patient outcome including survival. Therefore, it is difficult to define a surrogate endpoint in clinical trials. Furthermore, clinical guidelines such as the Response Assessment in Neuro-Oncology, Macdonald, and World Health Organization criteria lack clear descriptions of recurrence patterns. Therefore, categorizing these patterns of progression will allow for more sensitive evaluation of treatment failure and will help to differentiate the findings of progressive disease from other treatment complications.

Therefore, in the present study, a systematic review and meta-analysis of the current literature was performed in an attempt to categorize the radiological patterns of recurrence after bevacizumab treatment and to derive the pooled proportions of patients with recurrent malignant glioma with these different radiological patterns.

MATERIALS AND METHODS

This systematic review and meta-analysis were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (29).

Literature Search

A search of the MEDLINE and EMBASE databases was performed to identify original literature reporting radiological recurrence patterns in patients with recurrent malignant glioma after bevacizumab treatment failure. The following search terms were used: (((bevacizumab) OR (avastin) OR (antiangiogenic)) AND (((malignant astrocytoma) OR (high grade glioma) OR (glioblastoma) OR (malignant brain tumor)) AND ((failure) OR (recurrence) OR (resistance) OR (relapse) OR (progression)) AND (((magnetic resonance imaging) OR (MR imaging) OR (MRI) OR (radiology) OR (imaging) OR (image))). A beginning search date was not set and the literature search was updated until April 10, 2019. The search was limited to English-language publications. The bibliographies of relevant articles were also searched to identify additional relevant articles.

Inclusion Criteria

Studies satisfying the following criteria were included: 1) articles using bevacizumab in patients with recurrent malignant glioma; 2) studies classifying radiological recurrence patterns by MRI; 3) availability of sufficient information to calculate the pooled proportions of patients according to radiological recurrence pattern; and 4) original articles.

Exclusion Criteria

Studies or subsets of studies were excluded for any of the following: 1) case reports or case series including fewer than 20 patients; 2) letters, editorials, conference abstracts, systematic reviews or meta-analyses, consensus statements, guidelines, and review articles; 3) articles not focusing on the classification of radiologic recurrence patterns after bevacizumab treatment failure in patients with recurrent high-grade glioma; and 4) articles with, or with suspicion of, overlapping populations.

The literature search and selection were independently performed by two radiologists with 5 and 23 years of experience in brain tumor imaging, respectively.

Data Extraction

The following data were extracted using standardized forms: 1) article characteristics: authors, year of publication, institution, country of origin, duration of patient recruitment, total patient numbers, mean patient age, male-to-female ratio, patient numbers enrolled in the classification of the radiologic pattern of recurrence, and study design; 2) clinical information: analyzed target tumor, criteria for response assessment, history and types of prior treatment before recurrence, combination options with bevacizumab, bevacizumab regimen, and the kinds of chemotherapy agents used with bevacizumab; 3) information about the classification of the radiologic recurrence patterns: MRI sequences used for classification, definitions of the radiologic recurrence patterns, numbers of patients showing each pattern; and 4) progression-
free survival (PFS) according to the radiologic recurrence pattern.

Quality Assessment
Two reviewers independently performed data extraction and quality assessment using the Risk of Bias for Nonrandomized Studies (RoBANS) tool for nonrandomized controlled trials (30).

Data Synthesis and Analyses
The primary outcome of the current systematic review and meta-analysis was the identification of the pooled proportions according to the radiological recurrence patterns after bevacizumab use. The patterns were categorized as 1) geographically local versus non-local (distant, diffuse, and multifocal according to the classification described by Pope et al. (13)) and 2), for the predominant tumor portion, enhancing tumor versus non-enhancing tumor. In addition, subgroup analysis was performed to evaluate the clinical scenarios of the treatment combination options (bevacizumab treatment only versus bevacizumab combined with cytotoxic chemotherapy) occurring during bevacizumab treatment.

The pooled proportions were calculated using an inverse-variance weighting model (31-33). A random-effects meta-analysis of proportions was used to calculate the overall proportions. Study heterogeneity was evaluated using Higgins inconsistency index ($I^2$), with substantial heterogeneity indicated by $I^2$ values above 50% (34). All statistical analyses were conducted by one author (with 1 year of experience in conducting systematic reviews and meta-analyses) using the ‘meta’ package in R software (version 3.6.1, R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Literature Search
The article selection process is described in detail in Figure 1. The initial systematic literature search identified 1080 articles. Among these, 582 records were excluded in the MEDLINE and EMBASE database classification systems because they were case reports or case series, letters, editorials, conference abstracts, or review articles. After removing 14 duplicates, screening of the remaining 484 titles and abstracts yielded 30 potentially eligible articles. No additional article was identified in the searches of the bibliographies of these articles. After full-text reviews of the 30 provisionally eligible articles (4, 11-13, 15-28, 35-46), 13 were excluded because they were not in the field of interest (15, 35-41, 43-46) or had populations that were overlapping or had a suspicion of overlapping (42). Finally, the qualitative systematic review and quantitative meta-analysis included 17 studies (4, 11-13, 16-28).

Fig. 1. Flow diagram of study selection process.
Recurrence Patterns in Recurrent Glioblastoma

Characteristics of the Included Studies

The detailed characteristics of the included studies are reported in Table 1. The sizes of the original study populations ranged from 24 to 167 patients, with the mean patient ages ranging from 47–58 years, and the sizes of the populations included in the pooled analysis of the radiological patterns of recurrence ranging from 14 to 124 patients. Only one article reported a prospective study (24); the other studies were retrospective (4, 11-13, 16-23, 25-28). Seven studies included recurrent high-grade glioma (4, 16, 18, 23, 25, 26, 28) while the other 10 studies specifically included recurrent glioblastoma (11-13, 17, 19-22, 24, 27). The tumor response assessment criteria used after treatment varied according to the center from which the studies originated, as described in Table 1. The treatment strategies were also heterogeneous (Table 2). In terms of prior treatment history before bevacizumab, eight studies included patients having undergone surgery, chemotherapy, and radiation therapy (4, 11, 13, 18-21, 23, 24, 28); four studies included chemotherapy and radiation therapy (17, 22, 26, 27); two studies included chemotherapy (12, 16); and one study included radiation therapy (25). Four studies also included patients with a prior treatment history with an antiangiogenic agent (16, 21, 26, 28). Regarding combination options during bevacizumab treatment, eight studies included both patients treated with bevacizumab only and with bevacizumab in combination with chemotherapy (4, 11, 13, 18, 19, 26-28); four studies included only patients treated with bevacizumab in combination with chemotherapy (16, 21, 22, 24); two studies included only patients treated with bevacizumab only (12, 20); and one study included patients treated with bevacizumab only, with bevacizumab in combination with radiation therapy, and bevacizumab in combination with chemotherapy (17). One study did not provide detailed information on the treatment combination (23). The studies commonly tried to classify the radiological recurrence patterns after bevacizumab treatment failure according to its geographical distribution. Some studies also tried to categorize the predominant tumor portion as non-enhancing or enhancing (4, 11, 12, 16, 17, 21-23, 26-28).

Proportions according to the Radiologic Recurrence Pattern

The pooled proportion of a geographical radiological pattern of non-local recurrence was 38.3% (95% confidence interval [CI], 30.6–46.1%); the rates of distant, diffuse, and multifocal patterns were 6.7%, 29.2%, and 4.1%, respectively) (Table 3, Fig. 2). Study heterogeneity was substantial in the analysis ($I^2 = 77.7$%) The pooled proportion of non-enhancing tumors with a predominant radiologic recurrence pattern was 34.2% (95% CI, 27.3–41.5%). The study heterogeneity was borderline in this analysis ($I^2 = 50.1$%)

Subgroup Analysis

The pooled proportions of a geographical radiological pattern of non-local recurrence was 34.9% (95% CI, 22.8–49.4%) among the 222 patients treated with bevacizumab only (four studies) and 22.5% (95% CI, 9.5–44.6%) in the 264 patients treated with the combination with cytotoxic chemotherapy (seven studies).

PFS according to Radiologic Recurrence Pattern

We extracted PFS according to the radiologic recurrence patterns from the three enrolled studies for which this information was available (11, 19, 23). The PFS of local recurrence tended to be shorter than that for non-local recurrence according to the radiological recurrence pattern in the two studies, with unknown significance (local vs. non-local recurrence; 4.9 vs. 6.3 months and 3.9 vs. 4.2 months for the two studies). One study reported discordant data (local vs. non-local recurrence; 3.7 vs. 4.2 months) (23).

Quality Assessment of the Studies

The quality of the included studies was assessed according to the RoBANS criteria, the results of which are presented in Figure 3. All studies showed a low risk of bias in participant comparability, incomplete outcome data, outcome evaluation, confounding variables, and participant comparability. However, 12 of the 17 studies showed an unclear risk of bias in the blinding of participants and personnel domain, as they did not make clear statements in this regard (4, 16-20, 22-25, 27, 28). In the measurement of exposure domain, five studies showed a low risk of bias as multiple readers performed the radiologic assessment (11, 12, 17, 21, 26), five of 17 studies showed a high risk of bias because only a single reader assessed the radiologic response (13, 16, 20, 22, 24), and the other seven studies showed an unclear risk of bias (4, 18, 19, 23, 25, 27, 28). Finally, in the selection of patients domain, only one study showed a low risk of bias because of its prospective design (24) while the others showed high risks of bias due to their retrospective designs (4, 11-13, 16-23, 25-28).
| Source                  | Affiliation                                      | Duration of Patient Recruitment | Patient No. Total | Mean Age (Years) | Male: Female | Patient No. Radiological Recurrence Patterns | Study Design | Target Tumors Analyzed | Response Assessment                      |
|------------------------|--------------------------------------------------|---------------------------------|-------------------|------------------|-------------|---------------------------------------------|--------------|----------------------|----------------------------------------|
| Barajas et al., 2016 (18) | Oregon Health & Science University, USA           | Unclear                         | 26                | 52.6             | 13:13       | Retrospective                              | Recurrent HGG | T2 FLAIR and contrast enhancement volume and/or worsening neurologic status |
| Bloch et al., 2013 (19)  | University of California, USA                    | 2005–2009                       | 81                | 53.8             | 44:27       | Retrospective                              | Recurrent glioblastoma | RANO criteria + multi-disciplinary clinical assessment |
| Cachia et al., 2017 (11) | Medical University of South Carolina, USA        | January 2010–July 2014           | 64                | 51.5             | 38:26       | Retrospective                              | Recurrent glioblastoma | RANO criteria |
| Chamberlain, 2011 (20)   | University of Washington, USA                    | Unclear                         | 80                | 57.2             | 50:30       | Retrospective                              | Recurrent glioblastoma | NA |
| Desjardins et al., 2012 (21) | Duke University Medical Center, USA              | July 2007–October 2007           | 32                | 56.4             | 19:13       | Retrospective                              | Recurrent glioblastoma | Modified Macdonald criteria |
| Gállego Pérez-Larraya et al., 2012 (22) | Boulevard de l'Hôpital, France                  | May 2007–January 2010           | 78                | 58.3             | 48:30       | Retrospective                              | Recurrent glioblastoma | RECIST + FLAIR + RANO criteria |
| Iwamoto et al., 2009 (17) | Memorial Sloan-Kettering Cancer Center, USA      | October 2006–January 2009        | 37                | 54.3             | 26:11       | Retrospective                              | Recurrent glioblastoma | Macdonald criteria + FLAIR |
| Kim et al., 2015 (23)    | Samsung Medical Center, Seoul National University, Korea | September 2008–September 2014 | 71                | 47.3             | 36:28 (for 64) | Retrospective                              | Recurrent HGG | RANO criteria |
| Kim et al., 2017 (4)     | Chonnam National University, Korea               | August 2011–November 2015       | 24                | 47.5             | 10:14       | Retrospective                              | Recurrent HGG | RANO criteria |
| Narayana et al., 2009 (24) | New York University Medical Center, USA         | January 2005–June 2007          | 61                | 56.1             | 39:22       | Prospective                                | Recurrent glioblastoma | Macdonald criteria |
| Niyazi et al., 2014 (25) | University Hospital of Munich, Germany          | August 2008–July 2012           | 31                | 51.3             | 21:10       | Retrospective                              | Recurrent HGG | RANO criteria |
| Norden et al., 2008 (26) | Dana-Farber/Brigham and Women’s Cancer Center and Harvard Medical School, USA | June 2005–March 2007           | 55                | 50.2             | 32:23       | Retrospective                              | Recurrent HGG | Macdonald criteria |
| Nowosielski et al., 2014 (12) | Innsbruck Medical University, Austria; Heidelberg University, Germany | August 2007–January 2013        | 83                | 53.1             | 24:59       | Retrospective                              | Recurrent glioblastoma | RANO criteria |
| Pope et al., 2011 (13)   | University of California Los Angeles, USA        | July 2006–September 2007        | 167               | 55.2             | 69:31       | Retrospective                              | Recurrent glioblastoma | WHO response evaluation criteria |
| Schaub et al., 2013 (27) | University of Bonn Medical Center, Germany       | January 2008–December 2009      | 26                | NA               | 20:6       | Retrospective                              | Recurrent glioblastoma | RANO criteria |
| Thomas et al., 2018 (28) | Memorial Sloan-Kettering Cancer Center, USA      | Unclear                         | 32                | 56.4             | 25:7       | Retrospective                              | Recurrent HGG | NA |
| Zuniga et al., 2009 (16) | Henry Ford Health System, USA                    | November 2005–April 2008        | 51                | 51.1–53.2        | 33:18       | Retrospective                              | Recurrent HGG | Macdonald criteria |

FLAIR = fluid-attenuated inversion recovery, HGG = high grade glioma, NA = not available, RANO = Response Assessment in Neuro-Oncology, RECIST = response evaluation criteria in solid tumors, WHO = World Health Organization
### Table 2. Details of Clinical and Radiologic Examinations of Included Studies

| Source                        | Treatment History Prior to Bevacizumab | Combination Options with Bevacizumab | Regimen of Bevacizumab | Chemo-Agents with Bevacizumab | Sequences Used in Classification of Radiologic Recurrence Pattern | Classification of Radiologic Recurrence Pattern |
|-------------------------------|---------------------------------------|-------------------------------------|-------------------------|-----------------------------|---------------------------------------------------------------|-----------------------------------------------|
| Barajas et al., 2016 (18)    | Y Y Y NA                              | Only with RTx.                       | CPT, TMZ                | Y Y Y                       | 'Edematous,' 'Infiltrative'                                    |
|                              |                                       | With CTx.                            |                         |                             | 'Salt and pepper,' and 'Block' on DWI                          |
| Bloch et al., 2013 (19)      | Y Y Y NA                              | Y N Y                               | 10 mg/kg, every 2 weeks | Y Y N                       | 'Focal' (< 2 cm from original tumor)                         |
|                              |                                       |                                      |                         |                             | 'Disseminated' (> 2 cm from original tumor, contralateral, multifocal) |
|                              |                                       |                                      |                         |                             | 'Nodular,' 'Diffuse patchy,' and 'Non-enhancing' for 'Disseminated' |
| Cachia et al., 2017 (11)     | Y Y N NA                              | Y N Y                               | Irinotecan, lomustine, TPI-287, TMZ, vorinostat | Y Y N                       | Two classification schemes:                                  |
|                              |                                       |                                      |                         |                             | 1. by Nowosielski et al. (12): 'T2-diffuse, ' 'Contrast T1 flare-up, ' 'Non-responder, ' and 'T2-circumscribed' |
|                              |                                       |                                      |                         |                             | 2. by modified Pope et al. (13): classification: 'Local,' 'Diffuse,' and 'Distant' |
| Chamberlain, 2011 (20)       | Y Y Y NA                              | Y N N                               | NA                      | Y Y N                       | By Pope et al. (13): 'Local,' 'Distant,' 'Multifocal,' and 'Diffuse' |
| Desjardins et al., 2012 (21)| Y Y Partial                           | N N Y                               | TMZ                     | Y Y N                       | By Pope et al. (13): 'Local,' 'Distant,' 'Multifocal,' and 'Diffuse' |
| Gállego Pérez-Larraya et al., 2012 (22) | NA Y Y NA                             | N N Y                               | Irinotecan              | Y Y N                       | By Norden et al. (26) and Zuniga et al. (16): 'Local contrast-enhanced recurrence, 'New distant foci of enhancement,' and 'Diffuse' |
| Iwamoto et al., 2009 (17)    | NA Y Y NA                             | Y Y Y                               | Irinotecan, TMZ          | Y Y N                       | 'Local,' 'Predominantly non-enhancing,' and 'New multifocal enhancement' |
| Kim et al., 2015 (23)        | Y Y Y NA                              | Y NA Y N                            | NA                      | Y Y N                       | By Nowosielski et al. (12): 'T2-diffuse,' 'Contrast T1 flare-up, ' and 'Non-responder' |
| Kim et al., 2017 (4)         | Y Y Y NA                              | Y N Y                               | 10 mg/kg, every 2 weeks | Y Y N                       | 'Focal' and 'Diffuse'                                       |
| Narayana et al., 2009 (24)   | Y Y Y NA                              | N N Y                               | CPT, irinotecan         | Y Y N                       | 'Local,' 'Extensive gliomatosis,' and 'Diffuse without original lesion site' |
| Niyazi et al., 2014 (25)     | NA Y NA NA                            | Y N Y                               | NA                      | Y Y Y                       | 'In-field' and 'Ex-field'                                    |
| Norden et al., 2008 (26)     | NA Y Y Partial                        | Y N Y                               | CPT, carmustine, irinotecan, TMZ | Y Y N                       | 'Local (enhancement developed in contiguity with original tumor), ' 'Distant (new foci of enhancement distant from original tumor), ' and 'Diffuse (25% increase on FLAIR)' |
| Nowosielski et al., 2014 (12)| N Y N NA                              | Y Y N                               | 10 mg/kg, every 2 weeks | Y Y N                       | T2-diffuse (mainly T2 ill-defined diffuse infiltration), 'Contrast T1 flare-up (increased enhancement again), ' 'Non-responder, ' and 'T2-circumscribed (mainly local non-enhancing tumor)' |
DISCUSSION

The current systematic review and meta-analysis showed pooled proportions of 38.3% (95% CI, 30.6–46.1%) and 34.2% (95% CI, 27.3–41.5%) for a geographical radiologic pattern of non-local recurrence and a non-enhancing tumor-

Table 2. Details of Clinical and Radiologic Examinations of Included Studies (Continued)

| Source                          | Treatment History Prior to Bevacizumab | Combination Options with Bevacizumab | Regimen of Bevacizumab | Chemo-Agents with Bevacizumab | Sequences Used in Classification of Radiologic Recurrence Pattern | Classification of Radiologic Recurrence Pattern |
|---------------------------------|---------------------------------------|-----------------------------------|------------------------|-------------------------------|---------------------------------------------------------------|---------------------------------------------|
|                                 | Op. RTx. CTx. Anti-Angio Only With RTx. With CTx. | | | | CE-T1WI T2 FLAIR DWI | |
| Pope et al., 2011 (13)          | Y Y Y N                                 | Y N Y                             | 10 mg/kg, every 2 weeks | CPT                          | Y Y N                                                          | ‘Local (< 3 cm from tumor),’ ‘Distant (> 3 cm separate from tumor, single),’ ‘Multifocal (more than one enhancement foci),’ and ‘Diffuse (> 3 cm extending from tumor, single)’ |
| Schaub et al., 2013 (27)        | NA Y Y N                                | Y N Y                             | 10 mg/kg, every 2 weeks | Irinotecan                    | Y Y N                                                          | ‘Primary progressive,’ ‘FLAIR-only progression (mainly on T2/FLAIR)’ |
| Thomas et al., 2018 (28)        | Y Y Partial Y N                        | Y N Y                             | 10 mg/kg, every 2 weeks | Irinotecan, lomustine, TMZ    | Y Y N                                                          | ‘Local enhancement,’ ‘Distant enhancement,’ ‘Diffuse non-enhancing,’ and ‘Diffuse leptomeningeal’ |
| Zuniga et al., 2009 (16)        | NA NA Partial N N Y NA                  | Y Y Partial NA Y N                | 10 mg/kg, every 2 weeks | Irinotecan                    | Y Y N                                                          | ‘Local (< 2 cm from tumor),’ ‘Distant (at least one new foci of enhancement, > 2 cm from tumor),’ and ‘Diffuse (mainly on FLAIR)’ |

CE-T1WI = contrast-enhanced T1 weighted image, CPT = cisplatin, CTx. = chemotherapy, DWI = diffusion weighted image, N = not used, Op. = operation, RTx. = radiation therapy, TMZ = temozolomide, T2/FLAIR: T2 weighted image/fluid attenuated inversion recovery, Y = used

Table 3. Meta-Analytic Proportions of Radiologic Recurrence Patterns after Failure of Bevacizumab Treatment

| Source                          | Local Distant | Non-Local Diffuse | Total | Predominant Enhancing | Predominant Non-Enhancing | Total |
|---------------------------------|---------------|-------------------|-------|-----------------------|--------------------------|-------|
| Barajas et al., 2016 (18)       | 10            | 0                 | 16    | 26                    | NA                       | NA    |
| Bloch et al., 2013 (19)         | 59            | 0                 | 8     | 4                     | 71                       | NA    |
| Cachia et al., 2017 (11)        | 35            | 15                | 14    | 0                     | 64                       | 21    |
| Chamberlain, 2011 (20)          | 57            | 7                 | 9     | 7                     | 80                       | NA    |
| Desjardins et al., 2012 (21)    | 11            | 2                 | 8     | 0                     | 21                       | 16    |
| Gállego Pérez-Larraya et al., 2012 (22) | 28         | 11                | 17    | 0                     | 56                       | 28    |
| Iwamoto et al., 2009 (17)       | 17            | 0                 | 13    | 6                     | 36                       | 23    |
| Kim et al., 2015 (23)           | 25            | 0                 | 18    | 0                     | 43                       | 25    |
| Kim et al., 2017 (4)            | 11            | 0                 | 3     | 0                     | 14                       | 8     |
| Narayana et al., 2009 (24)      | 35            | 1                 | 14    | 0                     | 50                       | NA    |
| Niyazi et al., 2014 (25)        | 26            | 5                 | 0     | 0                     | 31                       | NA    |
| Norden et al., 2008 (26)        | 16            | 4                 | 4     | 0                     | 24                       | 20    |
| Nowosielski et al., 2014 (12)   | 52            | 0                 | 15    | 0                     | 67                       | 51    |
| Pope et al., 2011 (13)          | 55            | 2                 | 62    | 5                     | 124                      | NA    |
| Schaub et al., 2013 (27)        | 11            | 0                 | 6     | 0                     | 17                       | 11    |
| Thomas et al., 2018 (28)        | 23            | 1                 | 8     | 0                     | 32                       | 25    |
| Zuniga et al., 2009 (16)        | 13            | 4                 | 21    | 0                     | 38                       | 17    |
| Pooled proportions (%)          | 61.7          | 6.7               | 29.2  | 4.1                   | 100                      | 65.5  |
|                                | 61.7          | 38.3              | 100   |                       |                          | 100   |
| 95% CI                         | 53.9–69.5     | 30.6–46.1         | 58.1–72.1 | 27.3–41.5             |                          |       |

CI = confidence interval
predominant recurrence pattern, respectively. These findings of the existence and proportions of different types of recurrence provide comprehensive information on patients with recurrent high-grade glioma after bevacizumab treatment and could provide insights into surrogate endpoints for treatment failure in clinical trials of recurrent high-grade glioma.

The clinical and radiological challenges in the use of bevacizumab for the treatment of recurrent glioblastoma include the short response duration (less than 20 weeks), the short median overall survival (ranging from 31 to 74 weeks), and the difficulty in tissue confirmation for both patients and clinicians (1-4). Potential changes in enhancement or signal intensity patterns on MRI make it difficult to evaluate radiological recurrence (11-14). Several studies included in this systematic review and meta-analysis tried to classify the radiologic recurrence patterns after bevacizumab treatment failure in recurrent glioblastoma (4, 11-13, 16-28). Although these categorization methods mostly focused on the location and enhancement of recurrent disease, the categorization systems differed. Therefore, we need to organize the recurrence patterns systematically. In this systematic review and meta-analysis, the proportions of non-local tumor recurrence and non-enhancing tumor recurrence were substantial, at 38.3% and 34.2%, respectively.

Bevacizumab may alter tumor behavior due to its mechanism of action, which makes it harder to assess tumor response and detect treatment failure (5, 6). Regarding assessment of tumor response, several recent studies have shown that bevacizumab did not simply reduce tumor vascularity but rather normalized the microvascular environment and improved the distribution of the blood supply while also reducing tumor-associated edema or local inhomogeneity, reducing tissue hypoxia, and sensitizing the tumor to other treatments including radiation therapy, chemotherapy, and immunotherapy (47-49). Second, owing to its mechanism of action, recurrence on bevacizumab...
is often non-enhancing, distant, or diffuse disease. A non-enhancing, distant recurrence may be suggestive of a transition to a more aggressive phenotype (26, 50), although this suggestion remains controversial. Additionally, resistance to bevacizumab may occur, resulting in treatment failure. The reason for this resistance is unclear but may be mainly due to the complexity of the mechanism and the multiple bypass pathways at the molecular and angiogenesis level after bevacizumab use (7-10). Although no conclusive evidence supports that specific patterns of progression after bevacizumab treatment are associated with patient outcomes including survival, recognizing these patterns of progression will allow a more sensitive evaluation of treatment failure and will help to differentiate findings of progressive disease from other treatment complications.

Accurate assessment of treatment response is important because several studies have shown radiographic response to bevacizumab is correlated to PFS or overall survival (42, 51). However, the data are insufficient to determine changes in PFS according to the recurrence pattern. Several studies reported a relatively longer PFS for non-local recurrence than that for local tumor recurrence, while one study reported a discordant tendency (11, 19, 23). According to Nowosielski et al. (12), overall survival may be reflected by the recurrence patterns at the time recurrence diagnosis. Recently, non-local or non-enhancing tumor recurrence was suggested to be correlated with angiogenesis types such as ‘vessel co-option’ and ‘glioma stem-like cells,’ rather than with the ‘sprouting’ pattern of angiogenesis that is the target of bevacizumab (8). These results indicate that the patterns reflect different biological subgroups that should be addressed appropriately, according to their specific patterns. However, there were limitations in obtaining sufficient meta-analytic evidence regarding etiology due to the heterogeneity among the enrolled studies including response assessment criteria, treatment history prior to bevacizumab, various combination regimens of chemotherapy, etc. Further clarification with survival data analysis according to the radiologic patterns of recurrence and demonstration of the etiologies for the heterogeneity are needed.

This study has several limitations. First, the definitions of the classifications of radiologic patterns of recurrence after bevacizumab were not the same across studies. However, we tried to categorize them in our definitions of geographical and predominant tumor portion patterns. Second, each of the studies included a limited number of patients due to the scarcity of recurrent malignant glioma, which caused a reduction in the variety of endpoints assessed in this meta-analysis and which could be an important issue in the assessment of recurrence after bevacizumab in patients with recurrent high-grade glioma. Further investigation is needed. In addition, most studies were retrospective, resulting in a risk of bias in patient selection.

In conclusion, a substantial proportion of high-grade glioma patients showed non-local or non-enhancing radiologic patterns of recurrence after bevacizumab treatment. The identification of the radiologic pattern of recurrence could provide insight into surrogate endpoints of treatment failure in clinical trials of recurrent high-grade glioma.

Conflicts of Interest
The authors have no potential conflicts of interest to disclose.

ORCID iDS
Ho Sung Kim
https://orcid.org/0000-0002-9477-7421
Se Jin Cho
https://orcid.org/0000-0001-6450-7554
Chong Hyun Suh
https://orcid.org/0000-0002-4737-0530
Ji Eun Park
https://orcid.org/0000-0002-4419-4682

REFERENCES
1. Friedman HS, Prados MD, Wen PY, Mikkelson T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. *J Clin Oncol* 2009;27:4733-4740
2. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. *J Clin Oncol* 2009;27:740-745
3. Levin VA, Mendelssohn ND, Chan J, Stovall MC, Peak SJ, Yee JL, et al. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. *J Neurooncol* 2015;122:145-150
4. Kim JH, Jung TY, Hwang EC, Jung SH, Jung S, Kim IY, et al. Disease progression patterns of bevacizumab responders with recurrent malignant gliomas. *Oncol Lett* 2017;14:3529-3535
5. Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. *CNS Oncol* 2013;2:49-65
6. Piao Y, Liang J, Holmes L, Henry V, Sulman E, de Groot JF.
Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res 2013;19:4392-4403
7. Wang N, Jain RK, Batchelor TT. New directions in anti-angiogenic therapy for glioblastoma. Neurotherapeutics 2017;14:321-332
8. Hardee ME, Zagzag D. Mechanisms of glioma-associated neovascularization. Am J Pathol 2012;181:1126-1141
9. Kadambi A, Mouta Carreira C, Yun CO, Padera TP, Dolmans DE, Carmeli et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res 2001;61:2404-2408
10. Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001;61:7992-7998
11. Cachia D, Elshafeey NA, Kamiya-Matsuoka C, Hatami M, Alfaro-Munoz KD, Mandel JJ, et al. Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. J Neurooncol 2017;139:75-81
12. Nowosielski M, Wiestler B, Goebel G, Hutterer M, Schlemmer HP, Stockhammer GA, et al. Expression of hypoxia inducible factor 1-alpha in patients with recurrent glioblastoma. J Neurooncol 2014;118:1201-1208
13. Pope WB, Xia Q, Paton VE, Das A, Hambleton J, Kim HJ, et al. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 2011;76:432-437
14. Tuettenberg J, Grobholz R, Seiz M, Brockmann MA, Lohr F, Wenz F, et al. Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol 2019;145:1239-1244
15. Bähr O, Harter PN, Weise LM, You SJ, Mittelbronner M, Ronellenfitsch MW, et al. Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology 2014;83:227-234
16. Zuniga RM, Torcuator R, Jain R, Anderson J, Doyle T, Ellika S, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 2009;91:329-336
17. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200-1206
18. Barajas RF Jr, Butowski NA, Phillips JJ, Aghi MK, Berger MS, Chang SM, et al. The development of reduced diffusion following bevacizumab therapy identifies regions of recurrent disease in patients with high-grade glioma. Acad Radiol 2016;23:1073-1082
19. Bloch O, Safaee M, Sun MZ, Butowski NA, McDermott MW, Berger MS, et al. Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg 2013;115:1795-1801
20. Chamberlain MC. Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011;101:319-323
21. Desjardins A, Reardon DA, Coan A, Marcello J, Herndon JE 2nd, Bailey L, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 2012;118:1302-1312
22. Gállego Pérez-Larraza J, Lahitte M, Petrirena G, Reyez-Botero G, González-Aguilar A, Houllier C, et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 2012;14:667-673
23. Kim BS, Kim SK, Choi SH, Lee SH, Seol HJ, Nam DH, et al. Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. J Neurooncol 2015;124:101-110
24. Narayan A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 2009;110:173-180
25. Niizuya M, Jansen NL, Rottler M, Ganswindt U, Belka C. Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Radiat Oncol 2014;9:299
26. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-787
27. Schaub C, Greschus S, Seifert M, Waha A, Blasius E, Rasch K, et al. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Oncology 2013;85:191-195
28. Thomas A, Rosenblum M, Karimi S, DeAngelis LM, Omuro A, Kaley TJ. Radiographic patterns of recurrence and pathologic correlation in malignant gliomas treated with bevacizumab. CNS Oncol 2018;7:7-13
29. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gatzche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65-W94
30. Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol 2013;66:408-414
31. Kim KW, Lee J, Choi SH, Huh J, Park SH. Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers—Part I. General guidance and tips. Korean J Radiol 2015;16:1175-1187
32. Lee J, Kim KW, Choi SH, Huh J, Park SH. Systematic review and meta-analysis of studies evaluating diagnostic test accuracy: a practical review for clinical researchers—Part II. Statistical methods of meta-analysis. Korean J Radiol 2015;16:1188-1196
33. Suh CH, Park SH. Successful publication of systematic review and meta-analysis of studies evaluating diagnostic test accuracy. *Korean J Radiol* 2016;17:5-6
34. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-560
35. Artzi M, Bokstein F, Blumenthal DT, Aizenstein O, Liberman G, Corn BW, et al. Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study. *Eur J Radiol* 2014;83:1250-1256
36. Bahrami N, Piccioni D, Karunamuni R, Chang YH, White N, Delfanti R, et al. Edge contrast of the FLAIR hyperintense region predicts survival in patients with high-grade gliomas following treatment with bevacizumab. *AJNR Am J Neuroradiol* 2018;39:1017-1024
37. Burger MC, Breuer S, Cieplik HC, Harter PN, Franz K, Bähr O, et al. Bevacizumab for patients with recurrent multiform glioblastomas. *Int J Mol Sci* 2017;18. pii: E2469
38. Nowosielski M, Ellingson BM, Chiotol OL, Garcia J, Revil C, Radbruch A, et al. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. *Neuro Oncol* 2018;20:557-566
39. Pope WB, Lai A, Nghiempu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. *Neurology* 2006;66:1258-1260
40. Salloum R, DeWire M, Lane A, Goldman S, Hummel T, Chow L, et al. Patterns of progression in pediatric patients with high-grade glioma or diffuse intrinsic pontine glioma treated with bevacizumab-based therapy at diagnosis. *J Neurooncol* 2015;121:591-598
41. Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, et al. Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLarius trial. *J Cancer Res Clin Oncol* 2018;144:1581-1589
42. Shapiro LQ, Beal K, Goenka A, Karimi S, Iwamoto FM, Yamada Y, et al. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. *Int J Radiat Oncol Biol Phys* 2013;85:636-642
43. Toh CH, Liau CT, Wei KC, Castillo M. Baseline multicentric tumors, distant recurrences and leptomeningeal dissemination predict poor survival in patients with recurrent glioblastomas receiving bevacizumab. *J Neurooncol* 2019;142:149-159
44. Wick A, Dörner N, Schäfer N, Hofer S, Heiland S, Schemmer D, et al. Bevacizumab does not increase the risk of remote relapse in malignant glioma. *Ann Neurol* 2011;69:586-592
45. Wick W, Chiotol OL, Bendszus M, Mason W, Henriksson R, Saran F, et al. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. *Neuro Oncol* 2016;18:1434-1441
46. Yang D. Standardized MRI assessment of high-grade glioma response: a review of the essential elements and pitfalls of the RANO criteria. *Neurooncol Pract* 2016;3:59-67
47. Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. *J Clin Oncol* 2013;31:2205-2218
48. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. *Cancer Cell* 2014;26:605-622
49. Sorensen AG, Emblem KE, Polaskova P, Jennings D, Kim H, Ancukiewicz M, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. *Cancer Res* 2012;72:402-407
50. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. *Neuro Oncol* 2010;12:233-242
51. Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. *Neuro Oncol* 2011;13:143-151